Mingjie Yao

Mr. Mingjie Yao

Department of Anatomy and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Danli YangDanli Yang
Danli Yang
MYMingjie Yao
Mingjie Yao
YYYing Yan
Ying Yan
YLYanna Liu
Yanna Liu
XWXiajie Wen
Xiajie Wen
FLFengmin Lu
Fengmin Lu
Golgi protein 73 (GP73) is upregulated in a variety of liver diseases, yet the detailed mechanism is poorly characterized. We analyzed GP73 in a retrospective cohort including 4211 patients with chronic liver disease (CLD) or hepatocellular carcinoma (HCC). The effect of deoxycholic acid (DCA) and nuclear factor-kappa B (NF-κB) on expression and release of GP73 in Huh-7 and SMMC7721 cells were studied. A mouse study was used to confirm our findings in vivo. A positive correlation was found between serum GP73 and total bile acid (TBA) in cirrhotic patients (r = 0.540, p < 0.001), higher than that in non-cirrhotic CLD (r = 0.318, p < 0.001) and HCC (r = 0.353, p < 0.001) patients. In Huh-7 and SMMC7721 cells, DCA upregulated the expression and release of GP73 in a dose- and time-dependent manner. After overexpressing NF-κB p65, the promoter activity, GP73 messenger RNA (mRNA) level, and supernatant GP73 level were increased. The promotion effect of DCA on GP73 release was attenuated after inhibiting the NF-κB pathway. Mutating the binding sites of NF-κB in the sequence of the GP73 promoter led to a declined promoting effect of DCA on GP73. The upregulation role of DCA in GP73 expression through the NF-κB pathway was confirmed in vivo. In addition, exposure to DCA caused disassembly of Golgi apparatus. In summary, DCA upregulates the expression and release of GP73 via activating the NF-κB pathway and destroying the Golgi structure.

4 February 2020 in Disease Markers
Verified
Journal Article
Open access
PDF file
LWLeijie Wang
Leijie Wang
MYMingjie Yao
Mingjie Yao
SLShuhong Liu
Shuhong Liu
DYDanli Yang
Danli Yang
XWXiajie Wen
Xiajie Wen
FLFengmin Lu
Fengmin Lu
Aims. Persistent hepatic necroinflammatory damage almost always results in fibrosis/cirrhosis or even hepatocellular carcinoma. Therefore, the presence of active necroinflammation in the liver suggests that nonalcoholic fatty liver disease (NAFLD) patients are in urgent need of treatment. Unfortunately, alanine transaminase (ALT), a routine indicator of liver inflammatory damage, showed a poor performance in nonalcoholic steatohepatitis (NASH) patients. Thus, it will be valuable to find an alternative indicator to identify patients with hepatic necroinflammatory damage. In this study, we evaluated the diagnostic value of serum Golgi protein 73 (GP73) for hepatic necroinflammatory damage in patients with NASH. Methods. The clinical data of 201 patients with NASH diagnosed by liver biopsy according to the Brunt staging system were collected retrospectively. The in situ expression of GP73 protein was measured by immunohistochemistry. The receiver operating characteristic (ROC) curve was used to calculate the area under the ROC curve (AUROC) of serum GP73 for diagnosing hepatic necroinflammatory damage. Results. The serum GP73 levels of NASH patients increased with the aggravation of liver necroinflammation. The median levels significantly increased from 49.98 ng/ml (31.49, 75.05) for G0-1 to 76.61 ng/ml (48.68, 110.03) for G2 and to 116.44 ng/ml (103.41, 162.17) for G3 patients (G0-1 vs. G2, P<0.0001; G2 vs. G3, P=0.0228). In consistent, the gradual increase of GP73 protein expression in situ was also observed in liver tissue, in parallel with the increasing severity of necroinflammatory activity. Therefore, serum GP73 correlated well with the intensity of protein expression in liver tissue. The AUROCs of serum GP73 for G2 and G3 inflammatory activity were 0.742 (0.676 to 0.801) and 0.891 (0.840 to 0.931), respectively. Conclusions. GP73 is a valuable alternative serum marker reflecting the severity of hepatic necroinflammation in NASH patients.

15 January 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
MYMingjie Yao
Mingjie Yao
LWLeijie Wang
Leijie Wang
JWJianwen Wang
Jianwen Wang
YLYanna Liu
Yanna Liu
SLShuhong Liu
Shuhong Liu
FLFengmin Lu
Fengmin Lu
Background. There is lack of reliable serum biomarkers to reflect the severity of liver necroinflammation for those who suffer autoimmune liver diseases (AILDs). In this study, a previously established patient cohort was used to explore the potential of serum Golgi protein 73 (GP73) as a noninvasive marker of AILD-related liver necroinflammation. Methods. Serum GP73 concentration was measured in a retrospective cohort of 168 AILD patients, which included 74 patients with autoimmune hepatitis (AIH) and 94 with primary biliary cholangitis (PBC) who had undergone liver biopsy. Spearman’s correlation and multivariate analysis were used to evaluate the relationship between serum GP73 and liver necroinflammation. A receiver operating characteristic curve was constructed to evaluate the value of GP73 for the prediction of moderate or severe liver necroinflammation. The diagnostic value of serum GP73 was also compared with that of alkaline phosphatase (ALP) in patients with PBC. Histologically, immunohistochemical analysis was performed to assess hepatic GP73 expression. Results. Both the serum level and hepatic tissue expression of GP73 protein were aberrantly elevated and correlated well with the severity of necroinflammation in both AIH ( , ) and PBC ( , ) patients. The results here suggested that serum GP73 could be an independent biomarker to reflect the severity of liver necroinflammation. The AUROCs for GP73 to predict moderate necroinflammation (≥G2) and severe necroinflammation (≥G3) in patients with AIH were 0.828 and 0.832, respectively. Moreover, the AUROCs of serum GP73 for the identification of moderate necroinflammation (≥G2) ( , ) and severe necroinflammation (≥G3) ( , ) were superior to those of ALP (≥G2: , and ≥G3: ,

4 January 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
JTJingjing Tong
Jingjing Tong
MYMingjie Yao
Mingjie Yao
XMXiuying Mu
Xiuying Mu
LWLeijie Wang
Leijie Wang
XWXiajie Wen
Xiajie Wen
JHJinhua Hu
Jinhua Hu
As a hepatocellular carcinoma biomarker, serum Golgi protein 73 (GP73) is reportedly related to inflammation. Acute-on-chronic liver failure (ACLF) is characterized by severe systemic inflammation. In this study, we aimed to explore the association between the GP73 level and short-term mortality in patients with alcohol-associated liver disease-related ACLF (ALD-ACLF).

2 July 2025 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
YHYinchu Hu
Yinchu Hu
RLRuiqiong Li
Ruiqiong Li
MCMimi Chen
Mimi Chen
YCYidong Chen
Yidong Chen
QWQi Wang
Qi Wang
LRLihua Ren
Lihua Ren

6 September 2026 in Clinics
Verified
Journal Article
Open access
YWYamei Wei
Yamei Wei
MYMingjie Yao
Mingjie Yao
MZMei Zhang
Mei Zhang
SLShuhong Liu
Shuhong Liu
DYDanli Yang
Danli Yang
FLFengmin Lu
Fengmin Lu